Correspondence
Disparate results in studies of adalimumab in the treatment of hidradenitis suppurativa: comment on the article by Amano et al
First published: 17 February 2013
No abstract is available for this article.
References
- 1Amano M,
Grant A,
Kerdel FA.
A prospective open-label clinical trial of adalimumab for the treatment of hidradenitis suppurativa.
Int J Dermatol2010; 49: 950–955.
- 2Moul DK,
Korman NJ.
Severe hidradenitis suppurativa treated with adalimumab.
Arch Dermatol2006; 142: 1110–1112.
- 3Scheinfeld N.
Treatment of coincident seronegative arthritis and hidradenitis suppurativa with adalimumab.
J Am Acad Dermatol2006; 55: 163–164.
- 4Yamauchi P,
Mau N.
Hidradenitis suppurativa managed with adalimumab.
J Drugs Dermatol2009; 8: 181–183.
- 5Blanco R,
Martinez-Taboada VM,
Villa I,
et al.
Longterm successful adalimumab therapy in severe hidradenitis suppurativa.
Arch Dermatol2009; 145: 580–584.
- 6van der Zee HH,
Boer J,
Prens EP,
Jemec GB.
The effect of combined treatment with oral clindamycin and oral rifampicin in patients with hidradenitis suppurativa.
Dermatology2009; 219: 143–147.
- 7Sartorius K,
Lapins J,
Jalal S,
et al.
Bacteremia in patients with hidradenitis suppurativa undergoing carbon dioxide laser surgery: detection and quantification of bacteria by lysis-filtration.
Dermatology2006; 213: 305–312.
- 8Russ E,
Castillo M.
Lumbosacral epidural abscess due to hidradenitis suppurativa.
AJR Am J Roentgenol2002; 178: 770–771.
- 9Dixon WG,
Watson K,
Lunt M,
et al.
Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.
Arthritis Rheum2006; 54: 2368–2376.
